In eNOS KO groups undergoing experimental NEC, there was a significant improvement with CS supplementation in clinical sickness scores (eNOS KO NEC = 3 (Knowles et al., 2021; Neu & Walker, 2011), eNOS KO NEC + CS = 1[1–2.5], #p = 0.0070 | Figure 7b), macroscopic intestinal injury scores (eNOS KO NEC = 3 (Knowles et al., 2021; Neu & Walker, 2011), eNOS KO NEC + CS = 1[1–2.5], #p = 0.0007 | Figure 7c), and intestinal histology scores (eNOS KO NEC = 3 (Bazacliu & Neu, 2019; Knowles et al., 2021; Neu & Walker, 2011), eNOS KO NEC + CS = 1[1–1.5], #p = 0.0006 | Figure 7d). The gene discussed is NOS3; the disease is necrotizing enterocolitis.